Destiny Pharma notes release of UK Government's Vision and 5‐year action plan to help tackle anti‐microbial resistance(AMR), which includes additional investment in innovation
Government's plan consistent with Destiny Pharma's objective of developing novel anti‐infectives from its proprietary XFplatform.
Brighton, United Kingdom ‐ 24 January 2019 ‐ Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused
on the development of novel antimicrobial drugs, which address the global problem of anti‐microbial resistance (AMR),
notes the publication of the UK Government's 20‐year vision and 5‐year action plan on AMR which outlines how the
government will contribute to the global effort against AMR through optimising use of antimicrobials and investing in
innovation, supply and access.